Boomers Should Not ...
Health Care: Drugs
Pluristem Therapeutic (PSTI: NASDAQ)
$3.15 0.09 | 2.94%
05/22/13 - 04:00 PM ET
Growth Rates
| GROWTH RATES |
|---|
| REVENUE (Trailing 12 Quarters) |
| EARNINGS PER SHARE (Trailing 12 Quarters) |
| DIVIDENDS (Trailing 12 Quarters) |
Portfolios with PSTI
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- UserJaheer
- ContributorStocks Under-$10 Setting Up...
- UserBiotech88
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- User0730
Latest PSTI Headlines from TheStreet
- Pluristem Expands PLX Product Portfolio In Orthopedics And Sports Medicine 04.18.13 | 03:04 am
- United Therapeutics Receives Regulatory Approval To Commence Phase I Study Of Pluristem's PLX-PAD Cells For Pulmonary Arterial Hypertension 04.11.13 | 03:04 am
- Pluristem Announces Scientific And Investment Conferences For April 2013 04.10.13 | 02:04 am
- Pluristem Reports On The Progress Of Its Phase I/II Clinical Trial For The Treatment Of Muscle Injury 03.20.13 | 03:03 am
- United Therapeutics Moves Forward Towards A Phase I Study Of Pluristem's PLX-PAD Cells For Pulmonary Arterial Hypertension 02.26.13 | 09:02 am
- Pluristem Receives FDA Orphan Drug Status Designation For Treatment Of Aplastic Anemia 02.21.13 | 02:02 am
- 4 Biotech Stocks Under $10 Moving Higher 02.20.13 | 09:02 pm
- CORRECTING AND REPLACING -- Pluristem CEO To Participate In Key Roundtable Discussion At The 8th Annual New York Stem Cell Summit '13 02.13.13 | 07:02 am
- Pluristem CEO To Participate In Key Roundtable Discussion At The 8th Annual New York Stem Cell Summit '13 02.13.13 | 03:02 am
- Pluristem Takes Possession Of And Moving Into New State-of-the-Art Manufacturing Facility 01.30.13 | 03:01 am
Press Releases for PSTI
- The Rosen Law Firm Announces Investigation Of Securities Claims Against Pluristem Therapeutics, Inc. --- PSTI - Business Wire 12.20.12 | 07:12 pm
- Pluristem Therapeutics Raises Approximately $5 Million In Private Placement Of Common Stock - Business Wire 10.12.10 | 08:10 am
- Data From Clinical Trials Show Pluristem’s Placenta-Derived Cell Therapy Is Safe And Improves Quality Of Life And Efficacy Measurements In Patients With Critical Limb Ischemia - Business Wire 09.14.10 | 08:09 am
- Pluristem’s Placenta Derived Cells Chosen By European Commission’s Seventh Framework Program (FP7) Study For Treatment Of Diastolic Heart Failure (DHF) In Type 2 Diabetic Patients - Business Wire 08.30.10 | 08:08 am
- Pluristem's PLX Cells Found To Be Effective In Treating Neuropathic And Inflammatory Pain - Business Wire 08.09.10 | 08:08 am
- Pluristem Appoints Diabetic Neuropathy And Vascular Disease Expert, Dr. Aristidis Veves, To Its Scientific Advisory Board - Business Wire 08.04.10 | 08:08 am
- Pluristem Is Advancing Toward Two Phase IIb Clinical Trials For Treatment Of Critical Limb Ischemia And Moderate-Severe Claudication - Business Wire 06.28.10 | 08:06 am
- Pluristem’s Off-The-Shelf Placenta-Derived Cell Therapies - The Focus Of Presentations At Upcoming Investor And Medical Conferences - Business Wire 05.20.10 | 08:05 am
Partner Headlines for PSTI
- Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy - Seeking Alpha 03.28.13 | 09:03 am
- 3 Regenerative Medicine Companies That Could Deliver In 2013 - Seeking Alpha 01.22.13 | 09:01 am
- Orphan Status Update from Pluristem - Analyst Blog - Zacks 11.27.12 | 07:11 pm
- 4 Undervalued And Technically Oversold Healthcare Penny Stocks Poised To Bounce - Seeking Alpha 11.20.12 | 09:11 am
- 5 Bio-Pharmas On The Rise With Potential Groundbreaking And Lifesaving Treatments - Seeking Alpha 10.09.12 | 09:10 am
- Orphan Status Sought for PSTI Drug - Analyst Blog - NASDAQ 08.31.12 | 09:08 pm
- Orphan Status Sought for PSTI Drug - Analyst Blog - Zacks 08.31.12 | 06:08 pm
- Pluristem to Begin IC Phase II Trial - Analyst Blog - NASDAQ 08.24.12 | 10:08 pm
- Pluristem to Begin IC Phase II Trial - Analyst Blog - Zacks 08.24.12 | 06:08 pm
- Staring Down The Market With Futuristic Picks - Seeking Alpha 08.23.12 | 08:08 am
